Please login to the form below

Not currently logged in
Email:
Password:

glaucoma

This page shows the latest glaucoma news and features for those working in and with pharma, biotech and healthcare.

Astellas makes another gene therapy play with Juventas deal

Astellas makes another gene therapy play with Juventas deal

The option deal comes just a few weeks after Astellas acquired UK ocular gene therapy company Quethera for $109m, adding a potential treatment for glaucoma called QTA020V which is in in

Latest news

More from news
Approximately 3 fully matching, plus 37 partially matching documents found.

Latest Intelligence

  • Deal Watch August 2016 Deal Watch August 2016

    For example, Allergan has acquired ForSight Visions, a company that has developed a peri-ocular device that allows extended release of a drug to reduce intra-ocular pressure in glaucoma patients. ... 105. ForSight Visions. Allergan. Company acquisition.

  • Digital Business Models Digital Business Models

    For example, a pressure sensor in a smart contact lens monitors and controls intra-ocular pressure levels as well as identifies early cases of glaucoma.

  • Pharma deals in September 2015 Pharma deals in September 2015

    Acquisition - product. 445. Aquesys. Allergan. Implantable shunt for glaucoma. Acquisition - company.

  • Interview: Joseph Jimenez, Novartis Interview: Joseph Jimenez, Novartis

    R&D focus is on discovering new treatments for conditions including age-related macular degeneration (AMD), eye allergies, infections, inflammation, dry eye, glaucoma, cataract and refractive errors.

  • Opening the public's eyes

    Journalists from eight European countries attended, with 22 articles published during World Glaucoma Week. ... Accurate diagnosis of glaucoma can improve the likelihood of successful treatment and prevent blindness.

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

  • ThromboGenics bolsters leadership team ThromboGenics bolsters leadership team

    Schneider has 16 years’ experience of clinical drug development and prior to her new role, she most recently served Allergan as its vice president and therapeutic head of retina and glaucoma.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 3 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
huumun formerly PharmiWeb Solutions

huumun, is a digital transformation business. For us, digital transformation means using digital technologies, not just to turn an existing...

Latest intelligence

Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...

Infographics